64 search results for: pediatric
Identification and Management of AD Uncontrolled With Topical Therapies in Children
In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment
Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.
Charting the Future: Preventing the Atopic March
In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.
Charting the Future: Preventing the Atopic March
In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.
Atopic Dermatitis and the Risk of Developing Other Atopic Diseases
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses the significant risk of developing other atopic diseases among infants with early-onset atopic dermatitis.
On the Surface: Restoring the Skin Barrier in Patients with AD
In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.
Charting the Future: Preventing the Atopic March
In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
KOL Video Interview – Dr. Eric Simpson
In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.
